Sirtex wins $1.3m Start grant

By Melissa Trudinger
Thursday, 28 October, 2004

Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.

Targeted Hyperthermia Therapy uses the company's microsphere platform technology to deliver magnetic nanoparticles to tumours, followed by treatment with an alternating magnetic field to heat up the tumour causing death of the cancer cells.

The company has recently overcome some technical issues regarding the scale up of the treatment from animals to humans.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

The potential of AI technologies across the food supply chain

Larry Emdur's whisky brand appoints CEO

Fonterra's leadership changes confirmed

Driving food safety through digital traceability and transparency

Mars expands local pet food production with new $112.6m facility now open

How to extend the life of your motor bearings

From Dark Age to Imperial: what Age of Empires teaches us about instrumentation

WA Government to boost development of Collie green steel mill

Queensland increases investment in CopperString

Demystifying zero trust in OT

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available

SEKO IoT solutions revolutionise on-premise laundry dosing